SCHEMBL7718908

SCHEMBL7718908

CCCC(CC(CC)C(=O)OCC)P(=O)(O)O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
FDPS P14324 2/20 0.38
POLB P06746 1/20 0.38
METAP1 P53582 2/20 0.37
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CPB2 Q96IY4 1/20 0.34
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
EPHX2 P34913 1/20 0.32
PPARG P37231 1/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
KMT2A Q03164 1/20 0.32
CAD P27708 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7716640 0.87 CYP2D6 (0.40) CYP2D6CYP2C9CYP2C19FDPSPOLB
SCHEMBL7718882 0.77 CYP2D6 (0.39) CYP2D6CYP2C9CYP2C19CA1CA2
SCHEMBL17617131 0.76 CA2 (0.52) POLBCA1CA2CPB2ALOX15
Phosphoric Acid SCHEMBL27426833 0.76 ALDH1A1 (0.42) CYP2D6CYP2C9CYP2C19POLBCA1
SCHEMBL5679114 0.76 CA2 (0.52) POLBCA1CA2CPB2ALOX15
SCHEMBL13575662 0.76 CA2 (0.52) POLBCA1CA2CPB2ALOX15
SCHEMBL7718813 0.75 CYP2D6 (0.44) CYP2D6CYP2C9CYP2C19POLBCA1
SCHEMBL7715879 0.75 HSD17B10 (0.38) CYP2D6CYP2C9CYP2C19CPB2HSD17B10
SCHEMBL7716769 0.74 CYP2D6 (0.42) CYP2D6CYP2C9CYP2C19CPB2HSD17B10
Hydrochloric Acid SCHEMBL28448100 0.74 CA2 (0.50) POLBCA1CA2CPB2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed